Novo Nordisk | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
ANI Pharmaceuticals USD 144.86M 121K 2024-12
Aurora Cannabis CAD 108.71M 23.79M 2024-12
Bausch Health Companies USD 719M 124M 2024-09
Bristol-Myers Squibb USD 10.88B 529M 2025-03
Canopy Growth CAD 16.31M 69.8M 2024-12
Corcept Therapeutics USD 127.66M 9.62M 2024-12
Drreddys Laboratories INR 1.1B 743M 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
GlaxoSmithKline GBP 3.87B 678M 2024-12
Merck USD 13.24B 1.35B 2024-12
Novartis USD 8.87B 4.74B 2024-12
Novo Nordisk 57.02B 4.2B 2024-09
Pacira USD 276.77M 30.81M 2024-12
Perrigo USD 558.8M 904.7M 2024-12
Prestige Brands USD 50.87M 666K 2024-12
Sanofi 7.99B 550M 2025-03
Supernus Pharmaceuticals USD 69.33M 37.66M 2024-12
Zoetis USD 1.98B 275M 2024-12



Novo Nordisk Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Apr 2025.